Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.
Thorac Cancer
; 14(27): 2804-2810, 2023 09.
Article
em En
| MEDLINE
| ID: mdl-37589158
ABSTRACT
BACKGROUND:
This phase II trial was designed to evaluate the efficacy and safety of S-1 combined with weekly irinotecan as a second- or third-line treatment for patients with advanced or recurrent squamous cell lung cancer.METHODS:
Patients with a body surface area <1.25, 1.25-1.50, and >1.50 m2 received oral S-1 on days 1-14 at 80, 100, and 120 mg/day, respectively, and irinotecan on days 1 and 8 at 70 mg/m2 every 3 weeks. The primary endpoint was the overall response rate, and the secondary endpoints were progression-free survival, overall survival, and the incidence and severity of adverse effects.RESULTS:
Between September 2011 and December 2014, 30 patients were enrolled in this study. The overall response rate was 6.7% (95% confidence interval [CI] 0.8%-22.1%), and the disease control rate was 73.3%. The median progression-free survival was 3.0 months (95% CI 2.5-3.4 months), and the median overall survival was 10.5 months (95% CI 5.6-13.7 months). Grade 3/4 treatment-related adverse events were reported in ≥10% of the patients, including leukopenia (21%), neutropenia (21%), anemia (17%), anorexia (10%), and hypokalemia (10%).CONCLUSIONS:
Although the treatment-related adverse events were manageable, the combination of weekly irinotecan and S-1 did not have the expected effect.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Escamosas
/
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Tipo de estudo:
Etiology_studies
Limite:
Humans
País/Região como assunto:
Asia
Idioma:
En
Revista:
Thorac Cancer
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Japão